Ardelyx (ARDX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov27

Ardelyx Reports 22% Q3 Revenue Growth and Raises Full-Year IBSRELA Sales Guidance

22:51

Nov7

Ardelyx Inc. Presents New Evidentiary Studies on Tenapanor

21:05

Oct31

Ardelyx Inc. Reports Strong Revenue Growth for Flagship Drug Ibsrela

11:54

Oct30

Ardelyx released FY2025 Q3 earnings on October 30 After-Market EST, actual revenue USD 110.33 M (forecast USD 100.54 M), actual EPS USD -0.004 (forecast USD -0.0627)

23:00

Ardelyx released FY2025 9 Months Earnings on October 30 After-Market EST, actual revenue USD 282.11 M, actual EPS USD -0.2559

23:00

Oct28

Ardelyx Inc. Showcases Clinical Data for IBSRELA®

12:03

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 110.33 M, Net Income -969 K, EPS -0.004

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 97.66 M, Net Income -19.08 M, EPS -0.0795

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 74.11 M, Net Income -41.14 M, EPS -0.1724

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change